Repurposing of drugs for triple negative breast cancer: an overview
Open Access
- 13 July 2020
- journal article
- research article
- Published by Ecancer Global Foundation in ecancermedicalscience
- Vol. 14, 1071
Abstract
Repurposing of drugs for triple negative breast cancer: an overview Andrea Spini1,2, Sandra Donnini3, Pan Pantziarka4, Sergio Crispino4,5 and MarinKeywords
This publication has 37 references indexed in Scilit:
- A Network-Based Cancer Drug Discovery: From Integrated Multi-Omics Approaches to Precision MedicineCurrent Pharmaceutical Design, 2019
- The impact of aspirin use on breast cancer subtype and clinical courseJournal of Surgical Research, 2018
- Influencing the Tumor Microenvironment: A Phase II Study of Copper Depletion Using Tetrathiomolybdate in Patients with Breast Cancer at High Risk for Recurrence and in Preclinical Models of Lung MetastasesClinical Cancer Research, 2017
- The cost and value of cancer drugs – are new innovations outpacing our ability to pay?Israel Journal of Health Policy Research, 2016
- A randomized phase I trial of nanoparticle albumin-bound paclitaxel with or without mifepristone for advanced breast cancerSpringerPlus, 2016
- Triple-negative breast cancer: challenges and opportunities of a heterogeneous diseaseNature Reviews Clinical Oncology, 2016
- Response to angiotensin blockade with irbesartan in a patient with metastatic colorectal cancerAnnals of Oncology, 2016
- Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study)PLOS ONE, 2015
- Statin Prescriptions and Breast Cancer Recurrence Risk: A Danish Nationwide Prospective Cohort StudyJNCI: Journal of the National Cancer Institute, 2011
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007